{"id":1008,"date":"2000-09-01T12:04:00","date_gmt":"2000-09-01T10:04:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2000\/nochmals-clopidogrel-oder-ticlopidin-nach-stent-implantation-die-classics-studie"},"modified":"2000-09-01T12:04:00","modified_gmt":"2000-09-01T10:04:00","slug":"nochmals-clopidogrel-oder-ticlopidin-nach-stent-implantation-die-classics-studie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2000\/nochmals-clopidogrel-oder-ticlopidin-nach-stent-implantation-die-classics-studie","title":{"rendered":"Nochmals: Clopidogrel oder Ticlopidin nach Stent-Implantation? Die CLASSICS-Studie"},"content":{"rendered":"<p>Einer unserer Leser hatte im April auf die bemerkenswerte Situation hingewiesen, da\u00df in den Jahren 1998\/99 das bis dahin zur Verhinderung von Thrombosen nach Implantation koronarer Stents eingesetzte Regime mit Azetylsalizyls\u00e4ure (ASS) plus Ticlopidin (Tiklyd u.a.) zu Gunsten von ASS plus Clopidogrel (Plavix, Iscover) verlassen wurde, obwohl keine vergleichende Doppelblind-Studie vorlag (s. AMB 2000, 34, [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Einer unserer Leser hatte im April auf die bemerkenswerte Situation hingewiesen, da\u00df in den Jahren 1998\/99 das bis dahin zur Verhinderung von Thrombosen nach Implantation koronarer Stents eingesetzte Regime mit Azetylsalizyls\u00e4ure (ASS) plus Ticlopidin (Tiklyd u.a.) zu Gunsten von ASS plus Clopidogrel (Plavix, Iscover) verlassen wurde, obwohl keine vergleichende Doppelblind-Studie vorlag (s. AMB 2000, 34, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[74,77,76,2535,73,1172,882,2534,72],"class_list":["post-1008","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-acetylsalicylsaeure","tag-ass","tag-azetylsalizylsaeure","tag-classics-studie","tag-clopidogrel","tag-koronar-stent","tag-stent","tag-thrombotisch-thrombozytopenische-purpura","tag-ticlopidin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1008","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1008"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1008\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1008"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1008"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1008"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}